The main author Lindsay Fourman has researched and published many papers regarding Tesamorelin's various therapeutic effects on MAFLD among people with HIV. One can argue a "rapid diagnosis" of HIV lipodystrophy is as crucial as general, partial and genetic lipodystrophy if not more in order to avoid many health issues listed in this article. One of the issues with the disease is "limited experience among clinicians" so increasing the awareness and introducing much more timely diagnosis followed by treatment will certainly/significantly reduce the health risks among patients, general population and PLWH.
The point is the condition if not detected and treated in timely manner will be requiring more efforts to deal with its consequences! Tesamorelin 's sales has been lagging since the start and now is about time the clinician dealing with HIV patients start recognizing the importance of adequate medical care for a group of patients dealing with physical and psychological issues related to HIV.
"Lipodystrophy syndromes are rare diseases that can present with a broad range of symptoms. Delays in diagnosis are common, which in turn, may predispose to the development of severe metabolic complications and end-organ damage. Many patients with lipodystrophy syndromes are only diagnosed after significant metabolic abnormalities arise. Prompt action by clinical teams may improve disease outcomes in lipodystrophy syndromes. The aim of the Rapid Action Plan is to serve as a set of recommendations from experts that can support clinicians with limited experience in lipodystrophy syndromes."
https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2024.1383318/full